ATE254136T1 - Interaktions-fullensysteme zum nachweis von protein-interaktionen - Google Patents

Interaktions-fullensysteme zum nachweis von protein-interaktionen

Info

Publication number
ATE254136T1
ATE254136T1 AT95928118T AT95928118T ATE254136T1 AT E254136 T1 ATE254136 T1 AT E254136T1 AT 95928118 T AT95928118 T AT 95928118T AT 95928118 T AT95928118 T AT 95928118T AT E254136 T1 ATE254136 T1 AT E254136T1
Authority
AT
Austria
Prior art keywords
protein
binding
interaction
gene
protein interactions
Prior art date
Application number
AT95928118T
Other languages
English (en)
Inventor
Roger Brent
John M Mccoy
Timm H Jessen
Chanxing Wilson Xu
Original Assignee
Gen Hospital Corp
Inst Genetics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Inst Genetics Llc filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE254136T1 publication Critical patent/ATE254136T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0012Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1055Protein x Protein interaction, e.g. two hybrid selection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/35Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/80Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Vehicle Body Suspensions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95928118T 1994-07-20 1995-07-20 Interaktions-fullensysteme zum nachweis von protein-interaktionen ATE254136T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27808294A 1994-07-20 1994-07-20
PCT/US1995/009307 WO1996002561A1 (en) 1994-07-20 1995-07-20 Interaction trap systems for detecting protein interactions

Publications (1)

Publication Number Publication Date
ATE254136T1 true ATE254136T1 (de) 2003-11-15

Family

ID=23063609

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95928118T ATE254136T1 (de) 1994-07-20 1995-07-20 Interaktions-fullensysteme zum nachweis von protein-interaktionen

Country Status (8)

Country Link
US (3) US6004746A (de)
EP (2) EP0773952B1 (de)
JP (1) JP4064452B2 (de)
AT (1) ATE254136T1 (de)
DE (1) DE69532127T2 (de)
DK (1) DK0773952T3 (de)
ES (1) ES2210306T3 (de)
WO (1) WO1996002561A1 (de)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399296B1 (en) * 1994-07-20 2002-06-04 The General Hospital Corporation Interaction trap systems for detecting protein interactions
EP0773952B1 (de) * 1994-07-20 2003-11-12 The General Hospital Corporation Interaktions-fullensysteme zum nachweis von protein-interaktionen
EP0830459B1 (de) * 1995-04-11 2007-01-24 The General Hospital Corporation Reverse "two-hybrid"-systeme
EP1241265A3 (de) * 1996-04-26 2004-02-18 Massachusetts Institute Of Technology Screening-Verfahren für kleine Liganden
EP0907750B1 (de) * 1996-04-26 2002-09-18 Massachusetts Institute Of Technology Drei hybriden screening test
US5776689A (en) * 1996-07-19 1998-07-07 The Regents Of The University Of California Protein recruitment system
US5807708A (en) * 1996-07-30 1998-09-15 Millennium Pharmaceuticals, Inc. Conservin nucleic acid molecules and compositions
US5846722A (en) * 1996-10-16 1998-12-08 Terrapin Technologies, Inc. System to detect small molecule/peptide interaction
WO1998046796A1 (en) * 1997-04-11 1998-10-22 The Regents Of The University Of California A method of screening nucleotide sequences to identify disruptors or effectors of biological processes or pathways
AU3587599A (en) * 1997-11-28 1999-06-16 Invitrogen Corporation Single chain monoclonal antibody fusion reagents that regulate transcript ion in vivo
EP1035207A1 (de) * 1999-03-09 2000-09-13 MultiGene Biotech GmbH cDNA Moleküle der Mitglieder der Genfamilie, die für menschliche Fettsäuredesaturasen kodieren, und deren Verwendung in Diagnostik und Therapie
AU780061B2 (en) 1999-04-12 2005-02-24 Agensys, Inc. Transmembrane protein expressed in prostate and other cancers
EP1792989A1 (de) 1999-04-12 2007-06-06 Agensys, Inc. 13-Transmembrane Protein welches in Prostatakrebs exprimiert wird
US20060073150A1 (en) 2001-09-06 2006-04-06 Mary Faris Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
AU6054900A (en) * 1999-06-26 2001-01-31 Odyssey Pharmaceuticals, Inc. An in vivo library-versus-library selection of optimized protein-protein interactions
JP4373637B2 (ja) 1999-08-12 2009-11-25 アジェンシス,インコーポレイテッド ヒト前立腺癌において発現されるc型レクチン膜貫通抗原およびその使用
CA2385032C (en) 1999-10-05 2013-12-10 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US6893818B1 (en) * 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
US20030211495A1 (en) * 2000-03-08 2003-11-13 Richard Hopkins Reverse n-hybrid screening method
AU2002218786A1 (en) 2000-07-12 2002-01-21 Agensys, Inc. Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers
ATE403716T1 (de) 2000-08-28 2008-08-15 Agensys Inc Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen
WO2002022685A2 (en) * 2000-09-11 2002-03-21 Kufe Donald W Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
AU9630501A (en) 2000-09-26 2002-04-08 Univ Duke Rna aptamers and methods for identifying the same
WO2002051438A2 (en) 2000-12-22 2002-07-04 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (rgm) and its modulators
EP1958642A1 (de) * 2000-12-22 2008-08-20 Dana-Farber Cancer Institute Regulierung des Zellwachstums durch MUC1
US20030165873A1 (en) 2001-03-02 2003-09-04 Come Jon H. Three hybrid assay system
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
SG2011071982A (en) * 2001-05-25 2016-09-29 Univ Duke Modulators of pharmacological agents
US20040049024A1 (en) * 2001-12-07 2004-03-11 Geoff Clark Compositions and methods related to the minn1 tumor suppressor gene and protein
US20040086945A1 (en) * 2002-06-03 2004-05-06 The Procter & Gamble Company Hairless protein-interacting partner complexes and methods thereto
AU2003280420A1 (en) * 2002-06-26 2004-01-19 Yale University Modulators and modulation of the interacton between rgm and neogenin
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
US20060099713A1 (en) * 2002-10-01 2006-05-11 Buck Institute Targeted-assisted iterative screening (tais):a novel screening format for large molecular repertoires
CA2515699C (en) 2003-02-10 2015-01-27 Aya Jakobovits Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
WO2004092339A2 (en) * 2003-04-11 2004-10-28 Ilex Products, Inc. Modulation of muc1 mediated signal transduction
NZ572940A (en) 2003-05-30 2010-04-30 Agensys Inc Prostate stem cell antigen (PSCA) variants and subsequences thereof
GB0315248D0 (en) * 2003-06-30 2003-08-06 Hoffmann La Roche HCV regulated protein expression
US8129506B2 (en) 2003-10-24 2012-03-06 Genzyme Corporation Modulation of the interaction of MUC1 with MUC1 ligands
EP1533619B1 (de) 2003-11-20 2009-04-29 F. Hoffmann-Roche AG Spezifische Marker für Stoffwechselssyndrome
CA2556729A1 (en) * 2004-02-23 2005-09-09 Genzyme Corporation Muc1 antagonist enhancement of death receptor ligand-induced apoptosis
WO2005106042A2 (en) * 2004-04-22 2005-11-10 Regado Biosciences, Inc. Improved modulators of coagulation factors
JP4651663B2 (ja) 2004-05-28 2011-03-16 アジェンシス,インコーポレイテッド Pscaタンパク質に結合する抗体および関連分子
US8034553B2 (en) 2004-06-24 2011-10-11 Kimberly-Clark Worldwide, Inc. Biomarkers for wound healing
EP2444099A1 (de) 2005-03-31 2012-04-25 Agensys, Inc. An 161P2F10B-Proteine bindende Antikörper und zugehörige Moleküle
EP1928905B1 (de) 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
US9243243B2 (en) 2006-08-31 2016-01-26 Nexigen Gmbh Means and methods for detecting protein-peptide interactions
EP1927364A1 (de) 2006-12-01 2008-06-04 Ecole Normale Superieure De Lyon Polypetitde mit modulatorischer Wirkung auf Zellen
US7871784B2 (en) * 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
EP2034020A1 (de) * 2007-08-30 2009-03-11 Procomcure Biotech GmbH Verfahren zur Herstellung eines modifizierten Peptids
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
EP2101173A1 (de) * 2008-03-14 2009-09-16 Vivalis In-vitro-Verfahren zur Bestimmung, ob ein gegen ein Zielprotein aktiver Arzneimittelkandidat aktiv gegen eine Variante des besagten Proteins ist
US20110064202A1 (en) * 2008-05-15 2011-03-17 Koninklijke Philips Electronics N.V. Method and system for generating an x-ray beam
US8796415B2 (en) 2009-10-22 2014-08-05 Centre National De La Recherche Scientifique Inhibitors of guanine exchange factors and their use as anticancer drugs
BR112012013734A2 (pt) 2009-12-08 2017-01-10 Abbott Gmbh & Co Kg anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina.
WO2011083147A1 (en) 2010-01-08 2011-07-14 Cemm-Forschungsinstitut Für Molekulare Medizin Gmbh Wave1 inhibition in the medical intervention of inflammatory diseases and/or infections caused by a pathogen
US20130116304A1 (en) 2010-04-19 2013-05-09 Ernst R. Werner Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
RS57603B1 (sr) 2012-01-27 2018-11-30 Abbvie Deutschland Sastav i metod za dijagnozu i tretiranje bolesti povezanih sa degeneracijom neurita
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
CN116869964B (zh) 2014-12-24 2024-10-18 耐克西缪恩有限公司 用于免疫疗法的纳米颗粒组合物和方法
US11702477B2 (en) 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
EP3377080B1 (de) 2015-11-19 2024-02-14 Asclepix Therapeutics, LLC Peptide mit anti-angiogenen, anti-lymphangiogenen und anti-ödematösen eigenschaften und nanopartikelformulierungen
CN108883180B (zh) 2016-02-05 2023-07-07 奥里尼斯生物科学私人有限公司 Clec9a结合剂及其用途
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
CA3023883A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
EP3455245A2 (de) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutisches targeting von nichtzellulären strukturen
SG10202103032QA (en) 2016-10-04 2021-05-28 Asclepix Therapeutics Inc Compounds and methods for activating tie2 signaling
ES2917000T3 (es) 2016-10-24 2022-07-06 Orionis Biosciences BV Interferón-gamma mutante diana y usos del mismo
MX2019009255A (es) 2017-02-06 2019-11-05 Orionis Biosciences Nv Proteínas quiméricas dirigidas y sus usos.
US10906985B2 (en) 2017-02-06 2021-02-02 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
WO2018146074A1 (en) 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
US11674959B2 (en) 2017-08-03 2023-06-13 The Johns Hopkins University Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors
US12059476B2 (en) 2017-10-10 2024-08-13 The Johns Hopkins University Biodegradable biomimetic particles
GB2584211B (en) 2017-11-16 2023-05-24 Synthex Inc Selective modulation of protein-protein interactions
WO2019148089A1 (en) 2018-01-26 2019-08-01 Orionis Biosciences Inc. Xcr1 binding agents and uses thereof
KR102877915B1 (ko) 2018-02-05 2025-10-29 오리오니스 바이오사이언시즈 인코포레이티드 섬유아세포 결합제 및 이의 용도
CA3118892A1 (en) 2018-11-08 2020-05-14 Orionis Biosciences, Inc. Modulation of dendritic cell lineages
CA3129317A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
MA54955A (fr) 2019-02-15 2021-12-22 Integral Molecular Inc Anticorps anti-claudine 6 et leurs utilisations
WO2020198665A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Fibroblast activation protein binding agents and use thereof
JP7773376B2 (ja) 2019-05-15 2025-11-19 シンセックス, インコーポレイテッド タンパク質の選択的分解
EP4069731A4 (de) 2019-12-03 2024-05-29 Alamar Biosciences, Inc. Nukleinsäure-gekoppelter immun-sandwich-assay (nulisa)
GB202004514D0 (en) 2020-03-27 2020-05-13 Inst De Medicina Molecular Joaeo Lobo Antunes Treatment of Immunosuppressive Cancer
GB202009710D0 (en) * 2020-06-25 2020-08-12 Univ Bath Cross-linking methods
WO2022081804A1 (en) 2020-10-14 2022-04-21 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2023019171A1 (en) 2021-08-10 2023-02-16 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
US20250304677A1 (en) 2022-07-04 2025-10-02 Vib Vzw Blood-Cerebrospinal Fluid Barrier Crossing Antibodies
EP4598635A2 (de) 2022-10-06 2025-08-13 Bicara Therapeutics Inc. Multispezifische proteine und zugehörige verfahren
EP4626933A1 (de) 2022-11-30 2025-10-08 Integral Molecular, Inc. Gegen claudin 6 gerichtete antikörper mit bispezifischen formaten davon
CN121358771A (zh) 2023-04-03 2026-01-16 非营利性组织佛兰芒综合大学生物技术研究所 血-脑屏障穿越抗体
WO2025014773A1 (en) 2023-07-07 2025-01-16 Viridian Therapeutics, Inc. Methods of treating chronic thyroid eye disease
AU2024299328A1 (en) 2023-07-21 2026-01-22 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
WO2025093683A1 (en) 2023-11-03 2025-05-08 Neuvasq Biotechnologies Sa Wnt7 signaling agonists
WO2025136985A1 (en) 2023-12-17 2025-06-26 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
WO2025151502A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Modified antibodies
WO2025151492A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151496A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025160334A1 (en) 2024-01-26 2025-07-31 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
US20250353881A1 (en) 2024-05-16 2025-11-20 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025245111A1 (en) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Immunoreceptor targeting proteins and related methods
US20260015407A1 (en) 2024-07-15 2026-01-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory fusion proteins and related methods

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833080A (en) * 1985-12-12 1989-05-23 President And Fellows Of Harvard College Regulation of eucaryotic gene expression
US4980281A (en) * 1988-02-10 1990-12-25 Housey Gerard M Method of screening for protein inhibitors and activators
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
EP0496162A3 (en) * 1990-12-24 1993-09-01 Merck & Co. Inc. Peptide inhibitors of ras-gap interaction
US5270181A (en) * 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
US5885780A (en) * 1991-07-19 1999-03-23 University Of Utah Method of obtaining small conformationally rigid conopeptides
US5352660A (en) * 1991-10-31 1994-10-04 Mount Sinai Hospital Corporation Method for assaying for a substance that affects a SH2-phosphorylated ligand regulatory system
DE69333366T2 (de) * 1992-10-30 2004-09-16 The General Hospital Corp., Boston Ein neues zellzyklus kontrollprotein
US5695941A (en) * 1994-06-22 1997-12-09 The General Hospital Corporation Interaction trap systems for analysis of protein networks
EP0773952B1 (de) * 1994-07-20 2003-11-12 The General Hospital Corporation Interaktions-fullensysteme zum nachweis von protein-interaktionen
US6399296B1 (en) * 1994-07-20 2002-06-04 The General Hospital Corporation Interaction trap systems for detecting protein interactions
US6365344B1 (en) * 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
CA2244222A1 (en) * 1996-01-23 1997-07-31 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and rna molecules
US6114111A (en) * 1998-03-30 2000-09-05 Rigel Pharmaceuticals, Inc. Mammalian protein interaction cloning system

Also Published As

Publication number Publication date
WO1996002561A1 (en) 1996-02-01
JPH10504713A (ja) 1998-05-12
US20090130676A1 (en) 2009-05-21
DE69532127T2 (de) 2004-08-26
HK1012006A1 (en) 1999-07-23
DE69532127D1 (de) 2003-12-18
EP0773952B1 (de) 2003-11-12
DK0773952T3 (da) 2004-03-22
EP0773952A1 (de) 1997-05-21
EP1405911A1 (de) 2004-04-07
US6004746A (en) 1999-12-21
US6242183B1 (en) 2001-06-05
JP4064452B2 (ja) 2008-03-19
EP0773952A4 (de) 2000-01-19
ES2210306T3 (es) 2004-07-01

Similar Documents

Publication Publication Date Title
ATE254136T1 (de) Interaktions-fullensysteme zum nachweis von protein-interaktionen
DK0765389T3 (da) Cellesystemer havende specifik interaktion på peptide bindingspar
EP0672131A4 (de) Wechselwirkendes fallensystem zur isolierung neuer proteine.
ATE393228T1 (de) Fusionsproteine und deren verwendung zur messung von protease-aktivität
ATE253645T1 (de) Verfahren zur bestimmung von säugetier nukleinsäuren aus stuhlproben und dafür benötigte reagenzien
DE19781162T1 (de) Synchronisiertes Analyt-Testsystem
EP0977035A3 (de) System zur Messung des elektrischen Potentials durch eine Membrane
DE69607176D1 (de) Verfahren zur quantitativen bestimmung menschlichen akutphasen-serum-amyloid-a-proteins; rekombinantes protein; spezifischer antikörper
EP1403640A4 (de) Peptidimmobilisierte grundplatte und vefahren zum testen eines zielproteins unter verwendung derselben
DE69734204D1 (de) Lichtproduzierender biosensor
NO962084L (no) DNA sekvens som koder for en BMP reseptor
KR930002371A (ko) 핵산의 고정화 방법
AU2002229974A1 (en) Biochemical method and apparatus for detecting protein characteristics
WO2002050104A3 (en) Methods and cells for detecting modulators of rgs proteins
DE59914900D1 (de) Methode zur zellulären high-throughput-detektion von rezeptor-liganden-interaktionen
DE59914992D1 (de) Methode zur zellulären high-throughput-detektion von nukleären rezeptor-liganden-interaktionen
Durkee et al. Enzyme-linked coagulation assay: V. Amplified blotting assays using snake venom conjugates
JPS59141054A (ja) 電気泳動装置
ATE307893T1 (de) Verfahren zum nachweis von biologisch aktiven substanzen
Durkee Development of amplified detection systems for protein blotting using a solid phase coagulation assay.
Rand Blotting Techniques for the Detection of Protein Polymorphisms in Stains
NZ513455A (en) Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid system

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0773952

Country of ref document: EP